Biliary Tract Cancer Market Size Expected to Grow Major Growth by 2034, estimates DelveInsight

DelveInsight's report, "Biliary Tract Cancer Market Insights, Epidemiology, and Market Forecast-2034", provides a comprehensive analysis of biliary tract cancer, including historical trends, epidemiological projections, and market dynamics across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The report evaluates current treatment practices, pipeline therapies, and the market share of existing and emerging interventions. It presents the current and forecasted market size for biliary tract cancer from 2020 to 2034 across the seven major markets (7MM). In addition, it outlines treatment algorithms, key market drivers, barriers, and prevailing unmet needs, thereby identifying growth opportunities and assessing the future potential of the biliary tract cancer market.

Discover in-depth insights into the evolving Biliary Tract Cancer market - explore epidemiology trends, treatment landscapes, and emerging therapies shaping the future. Download sample report @ https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Biliary Tract Cancer Market Report
• In 2023, the total Biliary Tract Cancer Market Size was around USD 1000 million, which is expected to increase by 2034 during the study period (2020-2034) in the 7MM.
• On 27 October 2025, AstraZeneca announced a study is to measure the efficacy and safety of T-DXd with rilvegostomig or T-DXd monotherapy compared with gemcitabine plus cisplatin and durvalumab in patients with advanced treatment naïve HER2-expressing BTC.
• In 7MM, the United States accounted for the highest number of total incidence of Biliary Tract Cancer, which is around 30% of the total incident cases of Biliary Tract Cancer in the 7MM, in 2023.
• In the US, among the mutation-specific cases of Biliary Tract Cancer, TP53 cases were highest, followed by KRAS cases in 2023.
• Among the EU4 and the UK, Italy accounted for the highest number of Biliary Tract Cancer cases, followed by Germany, whereas Spain accounted for the lowest number of Biliary Tract Cancer cases.
• In 2023, as far as stage-specific cases are concerned, Stage IV accounted for the highest number of cases in Japan. These cases are anticipated to increase by 2034.
• The leading Biliary Tract Cancer companies such as Basilea Pharmaceutica, Zymeworks, BeiGene, Incyte Corporation, Loxo Oncology, Bayer, Roche, Genentech, QED Therapeutics, Agios Pharmaceuticals, Servier Pharmaceuticals, Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, Eisai, and TransThera Sciences (Nanjing), and others.
• Promising Biliary Tract Cancer Therapies such as PEMAZYRE (pemigatinib), IMFINZI (durvalumab), CTX-009, Zanidatamab, and others.

Explore Biliary Tract Cancer treatment algorithm and patient journeys across geographies. Get your free sample report here @ https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Biliary Tract Cancer Epidemiology Segmentation in the 7MM
• Total Incident Cases of Biliary Tract Cancer in the 7MM
• Age-specific Cases of Biliary Tract Cancer in the 7MM
• Stage-specific Cases of Biliary Tract Cancer in the 7MM
• Total Incident Cases of Biliary Tract Cancer by tumor location in the 7MM
• Mutation-specific Cases of Biliary Tract Cancer in the 7MM
• Treated Cases of Biliary Tract Cancer in the 7MM

Download the report to understand which factors are driving Biliary Tract Cancer epidemiology trends @ https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Biliary Tract Cancer Marketed Drugs

• PEMAZYRE (pemigatinib): Incyte
PEMAZYRE is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. This indication is approved under accelerated approval based on the overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). PEMAZYRE is a small molecule kinase inhibitor that targets FGFR1, 2, and 3 with IC50 values of less than 2 nM. PEMAZYRE also inhibited FGFR4 in vitro at a concentration approximately 100 times higher than those that inhibit FGFR1, 2, and 3. PEMAZYRE inhibited FGFR1-3 phosphorylation and signaling and decreased cell viability in cancer cell lines by activating FGFR amplifications and fusions that resulted in constitutive activation of FGFR signaling. Constitutive FGFR signaling can support the proliferation and survival of malignant cells. PEMAZYRE exhibited anti-tumor activity in mouse xenograft models of human tumors with FGFR1, 2, or FGFR3 alterations resulting in constitutive FGFR activation, including a patient-derived xenograft model of cholangiocarcinoma that expressed an oncogenic FGFR2-Transformer-2 beta homolog (TRA2b) fusion protein and the KG1 leukemia model that carries a translocation of FGFR1 (FGFR1OP2-FGFR1).

• IMFINZI (durvalumab): AstraZeneca
IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated in combination with gemcitabine and cisplatin as treatment of adult patients with locally advanced or metastatic Biliary Tract Cancer.The approval for the treatment of adult patients with locally advanced or metastatic by the US FDA was based on the results from the TOPAZ-1 Phase III trial. Expression of programmed cell death ligand-1 (PD-L1) can be induced by inflammatory signals (e.g., IFN-gamma) and can be expressed on both tumor cells and tumor-associated immune cells in the tumor microenvironment. PD-L1 blocks T-cell function and activation through interaction with PD-1 and CD80 (B7.1). By binding to its receptors, PD-L1 reduces cytotoxic T-cell activity, proliferation, and cytokine production. Durvalumab is a human immunoglobulin G1 kappa (IgG1?) monoclonal antibody that binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80 (B7.1). Blockade of PD-L1/PD-1 and PD-L1/CD80 interactions releases the inhibition of immune responses without inducing antibody-dependent cell-mediated cytotoxicity (ADCC). PD-L1 blockade with durvalumab led to increased T-cell activation in vitro and decreased tumor size in co-engrafted human tumor and immune cell xenograft mouse models.

Biliary Tract Cancer Emerging Therapies
• CTX-009: Compass Therapeutics
CTX-009 is a bispecific antibody that simultaneously blocks Delta-like ligand 4/Notch (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization. Preclinical and early clinical data of CTX-009 suggest that blockade of both pathways provides robust antitumor activity across several solid tumors, including colorectal cancer, gastric cancer, cholangiocarcinoma, pancreatic cancer, and non-small cell lung cancer. Partial responses to CTX-009 as monotherapy have been observed in heavily pre-treated patients with cancer who were resistant to currently approved anti-VEGF therapies.

• Zanidatamab: Jazz Pharmaceuticals/Zymeworks
Zanidatamab is a novel, late-stage oncology asset with the potential to transform the standard of care in multiple HER2-expressing cancers. It has demonstrated compelling data in biliary tract cancers and gastroesophageal adenocarcinoma with the potential to benefit patients across multiple tumor types.A pivotal Phase II clinical trial evaluating zanidatamab monotherapy in patients with previously treated advanced or metastatic HER2-amplified Biliary Tract Cancer.

Get In-Depth Knowledge on Biliary Tract Cancer Market Trends and Forecasts with DelveInsight @ https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Biliary Tract Cancer Companies
Basilea Pharmaceutica, Zymeworks, BeiGene, Incyte Corporation, Loxo Oncology, Bayer, Roche, Genentech, QED Therapeutics, Agios Pharmaceuticals, Servier Pharmaceuticals, Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, Eisai, and TransThera Sciences (Nanjing), and others.

Biliary Tract Cancer Market Outlook
Bile duct cancer begins when healthy cells in the bile duct change and grow out of control, forming a mass called a tumor. A tumor can be benign or cancerous. A benign tumor can grow but will not spread. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. Treatment options for the early-stage disease include surgery, followed by adjuvant chemotherapy. For patients with locally advanced and metastatic disease, the combination of gemcitabine and cisplatin has been shown to improve survival. After receiving initial approval in the United States in 2018 in the form of VITRAKVI, biliary tract cancer has seen approvals for various patient segments.

Biliary Tract Cancer Market Drivers
• Rising Incidence and Prevalence: Increasing global cases of biliary tract cancer, particularly in aging populations, drive demand for advanced therapies.
• Advances in Diagnostics: Improved imaging, molecular profiling, and biomarker identification enhance early detection and enable personalized treatment approaches.
• Emergence of Targeted Therapies: Approvals of drugs like PEMAZYRE, LYTGOBI, and FGFR/IDH inhibitors expand treatment options for biomarker-driven patient subsets.
• Immunotherapy Approvals: Checkpoint inhibitors such as IMFINZI and KEYTRUDA (with chemotherapy) demonstrate survival benefits in first-line settings, fueling adoption.
• Strong R&D Pipeline: Promising candidates (e.g., Tinengotinib, Zanidatamab, Rilvegostomig) are in late-stage development, expected to reshape the treatment paradigm.
• Increasing Healthcare Spending: Rising investments in oncology and broader access to advanced therapies stimulate market growth across the 7MM.

Biliary Tract Cancer Market Barriers
• High Treatment Costs: Targeted and immunotherapies are expensive, limiting accessibility in certain markets.
• Tumor Heterogeneity: Genetic diversity in BTC complicates treatment response and restricts broad applicability of targeted drugs.
• Late Diagnosis: Most patients present with advanced disease, reducing eligibility for curative interventions like surgery.
• Limited Awareness: Low public and clinical awareness in some regions delays diagnosis and timely treatment initiation.
• Regulatory and Reimbursement Challenges: Lengthy approval timelines and restrictive reimbursement policies hinder therapy uptake002E
• Adverse Effects and Resistance: Chemotherapy toxicity and resistance to targeted agents reduce long-term effectiveness.

Get In-Depth Knowledge on Biliary Tract Cancer Market Trends and Forecasts with DelveInsight @ https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Biliary Tract Cancer Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Biliary Tract Cancer Companies- Basilea Pharmaceutica, Zymeworks, BeiGene, Incyte Corporation, Loxo Oncology, Bayer, Roche, Genentech, QED Therapeutics, Agios Pharmaceuticals, Servier Pharmaceuticals, Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, Eisai, and TransThera Sciences (Nanjing), and others.
• Biliary Tract Cancer Therapies- PEMAZYRE (pemigatinib), IMFINZI (durvalumab), CTX-009, Zanidatamab, and others.
• Biliary Tract Cancer Therapeutic Assessment: Biliary Tract Cancer current marketed and Biliary Tract Cancer emerging therapies
• Pemphigus Vulgaris Market Dynamics: Pemphigus Vulgaris market drivers and Pemphigus Vulgaris market barriers
• Biliary Tract Cancer Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Biliary Tract Cancer Unmet Needs, KOL's views, Analyst's views, Biliary Tract Cancer Market Access and Reimbursement

Unlock Strategic Insights with DelveInsight's Comprehensive Biliary Tract Cancer Market Report @ https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Key Insights
2. Executive Summary
3. Biliary Tract Cancer Competitive Intelligence Analysis
4. Biliary Tract Cancer Market Overview at a Glance
5. Biliary Tract Cancer Disease Background and Overview
6. Biliary Tract Cancer Patient Journey
7. Biliary Tract Cancer Epidemiology and Patient Population
8. Biliary Tract Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. Biliary Tract Cancer Unmet Needs
10. Key Endpoints of Biliary Tract Cancer Treatment
11. Biliary Tract Cancer Marketed Products
12. Biliary Tract Cancer Emerging Therapies
13. Biliary Tract Cancer Seven Major Market Analysis
14. Attribute Analysis
15. Biliary Tract Cancer Market Outlook (7 major markets)
16. Biliary Tract Cancer Access and Reimbursement Overview
17. KOL Views on the Biliary Tract Cancer Market
18. Biliary Tract Cancer Market Drivers
19. Biliary Tract Cancer Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

About Us

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.